Cost-effectiveness randomized clinical trial on the effect of photobiomodulation therapy for prevention of radiotherapy-induced severe oral mucositis in a Brazilian cancer hospital setting
Lopes Martins AF, Nogueira TE, Morais MO, de Sousa-Neto SS, Oton-Leite AF, Valadares MC, Aires Freitas NM, Leles CR, Mendonça EF
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 17 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Gobierno
- Fundação de Amparo à Pesquisa do Estado de Goiás
- Subvenciones
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (307906-7); Fundação de Amparo à Pesquisa do Estado de Goiás (PPSUS – 201710267001233)
Según 2 financiadores declarados.
Publicación
- Publicado
- 2020-07-03 · Support Care Cancer · vol. 29 · número 3 · págs. 1245–1256
- Editorial
- Springer Science+Business Media
- Citado
- 34 citas · más que el 90% de estudios similares · 2.1× el promedio de su campo
- Referencias
- 38 trabajos
- Acceso
- De pago
- Áreas de investigación
- Oral health in cancer treatment · Health Systems, Economic Evaluations, Quality of Life · Oral Health Pathology and Treatment
- Palabras clave
- low-level laser therapy, radiotherapy-induced oral mucositis, cost-effectiveness, preventive dentistry, oral health-related quality of life, OHIP-14, radiotherapy interruption, cancer patients
- MeSH
- humans, stomatitis, double-blind method, quality of life, cancer care facilities, cost-benefit analysis, brazil, female, male, chemoradiotherapy, low-level light therapy
9 autores
- Allisson Filipe Lopes Martins🇧🇷Universidade Federal de Goiás
- Túlio Eduardo Nogueira🇧🇷Universidade Federal de Goiás
- Marília Oliveira Morais🇧🇷Hospital Araújo Jorge
- Sebastião Silvério Sousa‐Neto🇧🇷Universidade Federal de Goiás
- Angélica Ferreira Oton‐Leite🇧🇷Hospital Araújo Jorge
- Marize Campos Valadares🇧🇷Universidade Federal de Goiás
- Nilceana Maya Aires Freitas🇧🇷Hospital Araújo Jorge
- Cláudio Rodrigues Leles🇧🇷Universidade Federal de Goiás
- Elismauro Francisco Mendonça🇧🇷 · autor de correspondenciaUniversidade Federal de Goiás
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objectives
This study aimed to assess the cost-effectiveness of photobiomodulation therapy (PBMT) in association with a Preventive Oral Care Program (POCP) compared with POCP alone in the treatment of radiotherapy (RT)-induced oral mucositis (OM).
Methods
The cost-effectiveness was evaluated from the health provider perspective and conducted alongside a randomized, double-blind clinical trial. Participants were randomly assigned to either PBMT (n = 25) or control (n = 23) group. The PBMT group participants received PBMT associated with POCP. In the control group, patients were submitted to POCP alone. Costs were identified, quantified, and valued through observation and consultation of the hospital's financial sector database and estimated in Brazilian real and converted to international dollars using the purchasing power parity exchange rate. The incremental cost-effectiveness ratio (ICER) was estimated by considering the prevention of severe OM, interruption of RT, and oral health-related quality of life (OHRQoL) scores, measured by the OHIP-14 and patient-reported OM symptoms scale (PROMS).
Results
The incremental cost of PBMT was $857.35, and the cost per session was $25.69. The ICER was $ 2867.39 to avoid one case of severe OM and $ 2756.75 to prevent one interruption in RT due to OM. ICER to reduce 1 point in OHIP-14 and PROMS scores were $170.79 and $31.75, respectively.
Conclusion
PBMT is more cost-effective than POCP alone in preventing severe OM, worsening of the OHRQoL, and RT interruptions. PBMT is a promising therapy, especially to avoid interruptions in oncological treatment.
Trial registration
ReBEC-RBR-5h4y4n.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.